Alfaro PR

Language: Spanish
References: 20
Page: 313-317
PDF size: 321.80 Kb.

ABSTRACT

The antiphospholipid syndrome is an uncommon autoimmune disorder, that affects predominantly women and it is often associated with systemic lupus erythematosus, it is habitually manifested with abortions, premature childbirths or episodes of venous or arterial thrombosis, primarily of the brain. The responsible antibodies are: lupus anticoagulant, anticardiolipin, and anti B2-Glicoprotein-1.
Antiphospholipid syndrome is classified as a primary disorder when it does not appear in association with other autoimmune disorders and secondary when it is associated with disorders such as systemic lupus erythematosus or rheumathoid arthritis. The people who carry this syndrome must receive treatment promptly with anticoagulants to prevent its complications.

REFERENCES

1. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipidsyndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore).1998;77:195-207

2. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipidsyndrome: Clues to the pathogenesis from a series of 80 patients. Medicine(Baltimore). 2001;80:355-76.

3. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus:clinical and immunologic patterns of disease expression in a cohort of1,000 patients. Medicine (Baltimore) 1993;72:113-24.

4. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27

5. Conley CL, Hartman RC. A haemorrhagic disorder caused by circulating anticoagulant in patients withdisseaminated lupus erythematosus. J Clin Invest 1952:31:621-2.

6. Erkan D. Therapeutic and prognostic considerations in catastrophicantiphospholipid syndrome. Autoimmunity Rev 2006;6:98-103

7. Ferrara DE, Swerlick R, Harris EN, Meroni PL, Pierangeli S. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Arthritis Rheum 2002;46:S232

8. Gomez M, Monge N, et al. Síndrome antifosfolípido. Revista de la SEMG. 2004, 62: 157-163

9. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983;287:1088-9

10. Khamashta M, Mackworth-young C. Antiphospholipid (Hughes’) syndrome. .BMJ. 1997; 314:245.

11. Levine JS, Ware D, et al. The Antiphospholipid Syndrome. N Engl J Med. 2002; 346:752-762

12. Mazen, E, Amiram E. Thromboembolism in Patients with the “Lupus”. Type Circulating Anticoagulant, Arch Intern Med 1984; 144: 510-5.

13. Meroni P, Raschi E, Testoni C et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870–8.

14. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. Feb 2006;4(2):295-306.

15. R. Cervera y R.A. Ashersonb.Síndrome antifosfolipídico: nuevas perspectivasclínicas y terapéuticas. Reumatol Clin. 2005;1(4):183-6

16. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other `antiphospholipid’ autoantibodies. Blood 1994;84:2854-67

17. The APASS Writing Committee. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-584.

18. Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003;12:524-529.

19. Wassermann A, Neisser A, Bruck C. Eine serodiagnostiche Reaktionbei Syphilis. Deutsche Med Wochenschr 1906;32:745-6.

20. www.e2salud.juntaextremadura.netbibliotecashic092004_sindrome_antifosfolipido. pdf